Table 3.
Concordance of survivorship care plans with IOM recommendations (N=20 breast and 6 colorectal cancer plans)
| Components of IOM plan | Breast plans | Colorectal plans |
|---|---|---|
| Present N (%) | Present N(%) | |
| Date of diagnosis | 17 (85) | 5 (83) |
| Tumor characteristics described | 19 (95) | 5 (83) |
| Chemotherapy | ||
| Whether used | 19 (95) | 5 (83) |
| Name of drug | 18 (90) | 5 (83) |
| Dose | 14 (70) | 5 (83) |
| Date started | 15 (75) | 4 (67) |
| Date stopped | 16 (80) | 4 (67) |
| Treatment response | 0 (0) | 0 (0) |
| Toxicities | 11 (55) | 4 (67) |
| Radiation | ||
| Whether used | 17 (85) | 4 (67) |
| Dose | 15 (75) | 4 (67) |
| Location | 13 (65) | 4 (67) |
| Date started | 13 (65) | 4 (67) |
| Date stopped | 16 (80) | 4 (67) |
| Treatment response | 1 (5) | 0 (0) |
| Toxicities | 8 (40) | 4 (67) |
| Surgery | ||
| Whether used | 19 (95) | 5 (83) |
| Procedure | 19 (95) | 5 (83) |
| Date | 19 (95) | 4 (67) |
| Complications | 9 (45) | 4 (67) |
| Hormone therapy | ||
| Whether used | 16 (80) | N/A |
| Date started | 14 (70) | N/A |
| Date stopped | 11 (55) | N/A |
| Treatment response | 1 (5) | N/A |
| Toxicities | 6 (30) | N/A |
| Clinical trials | ||
| Whether participated | 8 (40) | 2 (33) |
| Date | 3 (15) | 0 (0) |
| Number and other identifying info | 6 (30) | 1 (17) |
| Psychosocial services provided | 1 (5) | 0 (0) |
| Nutritional services provided | 0 (0) | 0 (0) |
| Other supportive services provided | 0 (0) | 0 (0) |
| Name(s) of cancer care provider(s) who treated them | 17 (85) | 5 (83) |
| Contact information for cancer care provider(s) who treated them | 12 (60) | 3 (50) |
| Continuing cancer care key contact | 14 (70) | 3 (50) |
| Contact information for continuing primary care | 9 (45) | 3 (50) |
| Information on when to visit primary care provider | 9 (45) | 2 (33) |
| Likely course of recovery from treatment toxicities | 1 (5) | 0 (0) |
| Recommendation for 2nd primary cancer/recurrence surveillance | 20 (100) | 6 (100) |
| Information regarding who provides 2nd primary surveillance | 10 (50) | 4 (67) |
| Information regarding timing of 2nd primary surveillance | 15 (75) | 6 (100) |
| Recommendation for screening for other cancers | 16 (80) | 4 (67) |
| Information regarding who provides cancer screening | 9 (45) | 1 (17) |
| Information regarding timing of cancer screening | 12 (60) | 3 (50) |
| Recommendation for other tests (cholesterol, anemia) | 9 (45) | 4 (67) |
| Information regarding who provides other tests | 2 (10) | 2 (33) |
| Information on timing of other tests | 7 (35) | 2 (33) |
| Late and long term effects of treatments | 8 (40) | 1 (17) |
| Possible signs of recurrence and second tumors | 13 (65) | 0 (0) |
| Marital/partner, sexual functioning, work, parenting effects | 6 (30) | 2 (33) |
| Potential need for future psychosocial support | 8 (40) | 3 (50) |
| Insurance, employment, legal aid, financial assistance | 1 (5) | 0 (0) |
| Recommendations for healthy behaviors | 14 (70) | 4 (67) |
| Recommendations for relatives’ screening if at increased risk | 0 (0) | 0 (0) |
| Genetic counseling information to identify high risk people | 6 (30) | 1 (17) |
| Information on chemoprevention | 0 (0) | 0(0) |
| Referrals to other providers | 3 (15) | 1(17) |
| Cancer-related resources | 7 (35) | 1 (17) |
| Categories of components | ||
| Treatment history | 19 (95) | 5 (83) |
| Expectations for survivorship experiences | 4 (20) | 0 (0) |
| Recommendations for care | 11 (55) | 3 (50) |
| Information on who is responsible for ongoing testing | 2 (10) | 1 (17) |